查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1789868

Dupixent 市場規模、佔有率和趨勢分析報告：按適應症、分銷管道、地區和細分市場預測，2025 年至 2033 年

Dupixent Market Size, Share & Trends Analysis Report By Indication (Atopic Dermatitis, Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Obstructive Pulmonary Disease ), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Dupixent 市場摘要

預計 2024 年全球 Dupixent 市場規模為 141.5 億美元，預計 2033 年將達到 275.8 億美元，2025 年至 2033 年的複合年成長率為 7.70%。 Dupixent 產業反映了從傳統治療方法轉向生技藥品的轉變。

這一成長是由全球 2 型發炎性疾病盛行率的不斷上升所驅動，包括異位性皮膚炎、氣喘和伴隨鼻息肉的慢性鼻竇炎，以及近期監管部門核准的水痘天皰瘡和嗜伊紅性食道炎新適應症。市場成長是由治療 2 型發炎性疾病的需求所驅動。賽諾菲和再生元開發的 Dupixent 在臨床試驗中已證明其有效性和安全性，在治療異位性皮膚炎和氣喘等疾病方面優於皮質類固醇等傳統選擇。這一轉變是由全球盛行率的不斷上升所支持的，據報道，到 2024 年，將有超過 2 億人患有異位性皮膚炎，超過 3 億人患有氣喘。

Dupixent 的市場擴張主要由研發驅動，並得到新治療領域臨床試驗的支持。正在進行的試驗，例如用於治療慢性自發性蕁麻疹的 LIBERTY-CSU CUPID 試驗和用於治療嗜伊紅性食道炎和用於治療水痘天皰瘡的核准（預計於 2024 年 1 月）預計將提高患者合格，並增強其在 2033 年之前的長期產生收入。這些努力得到了真實世界證據的支持，正在鞏固 Dupixent 在發炎性疾病和罕見免疫適應症領域的地位。

賽諾菲與再生元的全球合作有助於加速監管核准，並強化市場進入平台。美國藥物管理局 (FDA) 於2025年6月核准Dupixent用於治療慢性阻塞性肺病 (COPD) 和水痘天皰瘡，這標誌著一項戰略里程碑，將Dupixent的核准適應症擴展至九種，包括伴有鼻息肉的慢性鼻竇炎和結節性癢疹。這鞏固了Dupixent在白細胞介素抑制劑領域的地位，而其在北美、歐洲和亞太地區的全球擴張正由協調一致的監管和商業策略推動。

在美國和日本等主要市場，專利保護期至2033年，降低了中期生物相似藥帶來的競爭風險。此外，製造流程的複雜性和專業化設施也阻礙力了新進入者的進入。市場擴張的機會仍然存在，尤其是在拉丁美洲、中東和非洲等尚未開發的地區。巴西和沙烏地阿拉伯等國家擁有龐大的患者群體，這得益於醫療改革和生技藥品需求的不斷成長。在地化的定價策略和分銷夥伴關係預計將促進在地化藥物的取得。

歐洲孤兒藥專營權等監管激勵措施，加上強大的開發平臺，支撐了持續成長。然而，2033年後的市場動態，包括歐洲和亞太地區的生物相似藥准入和定價限制，凸顯了製定適應性報銷策略和患者可及性計劃以保持盈利的必要性。

目錄

第1章調查方法與範圍

第2章執行摘要

3. Dupixent 市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 Dupixent 市場：按適應症進行的業務分析

  • 2024 年及 2033 年各適應症市場佔有率分析
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（按適應症，2021-2033 年）
  • 異位性皮膚炎（AD）
  • 氣喘
  • 慢性鼻竇炎伴隨鼻息肉（CRSwNP）
  • 慢性阻塞性肺病（COPD）
  • 其他

5. Dupixent 市場：按分銷管道進行的業務分析

  • 2024 年及 2033 年通路市場佔有率分析
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥局
  • 其他

第6章：Dupixent 市場：區域估計與趨勢分析

  • 2024 年及 2033 年區域市場佔有率分析
  • 地理細分儀表板
  • 市場規模及預測趨勢分析（按地區，2021-2033）
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Sanofi
    • Regeneron
Product Code: GVR-4-68040-657-9

Dupixent Market Summary

The global dupixent market size was estimated at USD 14.15 billion in 2024, and is projected to reach USD 27.58 billion by 2033, growing at a CAGR of 7.70% from 2025 to 2033. The Dupixent industry reflects a transition from traditional therapies to biologics.

Anchored by its innovative interleukin-4 and interleukin-13 inhibition mechanism, this growth is driven by the increasing global prevalence of Type 2 inflammatory diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, along with recent regulatory approvals for new indications such as bullous pemphigoid and eosinophilic esophagitis. The market growth is driven by the need for treatments addressing Type 2 inflammatory diseases. Dupixent, developed by Sanofi and Regeneron, demonstrates efficacy and safety in clinical trials, surpassing conventional options like corticosteroids for conditions including atopic dermatitis and asthma. This shift is supported by increasing global prevalence, with over 200 million atopic dermatitis patients and 300 million asthma cases reported in 2024.

Research and development efforts are a key driver of the Dupixent market's expansion, supported by clinical trials across new therapeutic areas. Ongoing studies such as LIBERTY-CSU CUPID for chronic spontaneous urticaria and trials in allergic fungal rhinosinusitis aim to broaden the drug's reach to new patient populations. Pediatric trials for eosinophilic esophagitis and approved use in bullous pemphigoid (January 2024) are expected to enhance patient eligibility and strengthen long-term revenue generation through 2033. These initiatives, supported by real-world evidence, are increasing Dupixent's positioning across inflammatory and rare immunologic indications.

Sanofi and Regeneron's global collaboration facilitates accelerated regulatory approvals and strengthens market access infrastructure. U.S. FDA approvals in June 2025 for COPD and bullous pemphigoid mark strategic milestones, expanding Dupixent's approved indications to nine, including chronic rhinosinusitis with nasal polyps and prurigo nodularis. This has reinforced the drug's standing in the interleukin inhibitor class, with global rollout in North America, Europe, and Asia Pacific driven by a coordinated regulatory and commercialization strategy.

Patent protection in major markets such as the U.S. and Japan until 2033 reduces biosimilar competition risk in the medium term. Additionally, manufacturing complexity and specialized facilities act as deterrents for new entrants. Market expansion opportunities remain in underpenetrated regions, particularly Latin America and the Middle East & Africa. Countries such as Brazil and Saudi Arabia present significant patient pools, supported by healthcare reforms and increasing biologics demand. Localized pricing strategies and distribution partnerships are expected to drive regional access.

Regulatory incentives such as orphan drug exclusivity in Europe, combined with a strong development pipeline, support sustained growth. However, post-2033 market dynamics, including biosimilar entry and pricing constraints in Europe and Asia Pacific, highlight the need for adaptive reimbursement strategies and patient access programs to maintain profitability.

Global Dupixent Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Dupixent market report based on indication, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Atopic Dermatitis (AD)
  • Asthma
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Dupixent Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Dupixent Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Atopic Dermatitis (AD)
    • 4.4.1. Atopic Dermatitis (AD) Market, 2021 - 2033 (USD Million)
  • 4.5. Asthma
    • 4.5.1. Asthma Market, 2021 - 2033 (USD Million)
  • 4.6. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    • 4.6.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, 2021 - 2033 (USD Million)
  • 4.7. Chronic Obstructive Pulmonary Disease (COPD)
    • 4.7.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Dupixent Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Dupixent Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Dupixent Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Sanofi
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Regeneron
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Dupixent market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 5. Global Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 8. North America Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 10. U.S. Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 12. Canada Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 14. Mexico Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 17. Europe Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 19. UK Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 21. Germany Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 23. France Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 25. Italy Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 27. Spain Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 29. Norway Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 31. Denmark Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 33. Sweden Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37. Japan Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 38. Japan Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 40. China Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 42. India Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 44. Australia Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 46. South Korea Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 48. Thailand Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 51. Latin America Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 53. Brazil Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 55. Argentina Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 60. South Africa Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 64. UAE Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Dupixent market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Dupixent market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Dupixent market dynamics
  • Fig. 12 Dupixent market: Porter's five forces analysis
  • Fig. 13 Dupixent market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Atopic Dermatitis (AD) market, 2021 - 2033 (USD Million)
  • Fig. 16 Asthma market, 2021 - 2033 (USD Million)
  • Fig. 17 Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) market, 2021 - 2033 (USD Million)
  • Fig. 18 Chronic Obstructive Pulmonary Disease (COPD) market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 Dupixent market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework